MARKET

PULM

PULM

Pulmatrix
NASDAQ
6.61
+0.31
+4.92%
Closed 16:00 04/30 EDT
OPEN
6.65
PREV CLOSE
6.30
HIGH
6.68
LOW
6.35
VOLUME
5.66K
TURNOVER
--
52 WEEK HIGH
10.40
52 WEEK LOW
1.720
MARKET CAP
24.14M
P/E (TTM)
-2.5255
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PULM last week (0421-0425)?
Weekly Report · 2d ago
Weekly Report: what happened at PULM last week (0414-0418)?
Weekly Report · 04/21 09:46
Weekly Report: what happened at PULM last week (0407-0411)?
Weekly Report · 04/14 09:43
Weekly Report: what happened at PULM last week (0331-0404)?
Weekly Report · 04/07 09:42
Weekly Report: what happened at PULM last week (0324-0328)?
Weekly Report · 03/31 09:46
Pulmatrix Reports 2024 Financials and Merger Plans
TipRanks · 03/25 03:57
Weekly Report: what happened at PULM last week (0317-0321)?
Weekly Report · 03/24 09:42
Based on the provided financial report articles, I generated the title for the article: "Form 10-K: Pulmatrix, Inc. (0001574235) Annual Report for the fiscal year ended December 31, 2024" Please note that the title may not be exact, as the provided text appears to be a financial report in XML format, and the title may not be explicitly stated.
Press release · 03/21 12:41
More
About PULM
More
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
Recently
Symbol
Price
%Change

Webull offers Pulmatrix Inc stock information, including NASDAQ: PULM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PULM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PULM stock methods without spending real money on the virtual paper trading platform.